CytomX Therapeutics. has been granted a patent for a method that involves partially reducing activatable antibodies to selectively conjugate therapeutic or diagnostic agents. This process utilizes tris(2-carboxyethyl)phosphine (TCEP) to reduce interchain disulfide bonds while preserving intrachain bonds within a masking moiety. GlobalData’s report on CytomX Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CytomX Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. CytomX Therapeutics's grant share as of June 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody conjugation methods for selective agent placement
The patent US11992528B2 outlines a method for partially reducing an activatable antibody and conjugating an agent to it, enhancing the selectivity of agent placement. The process involves the use of a reducing agent, specifically tris(2-carboxyethyl)phosphine (TCEP), to reduce interchain disulfide bonds in the antibody while preserving intrachain disulfide bonds within a masking moiety (MM). The method specifies a reducing agent-to-antibody ratio of less than 5:1 and a reduction time ranging from 30 minutes to 2 hours. Following this reduction, an agent, which may include toxins or detectable moieties, is conjugated to the antibody via thiol groups. The activatable antibody is designed to bind specifically to a target, with the MM inhibiting this binding in its uncleaved state, and a cleavable moiety (CM) that serves as a substrate for proteases.
Further claims detail the structural arrangements of the activatable antibody, the nature of the agents that can be conjugated, and the characteristics of the MM and CM. The MM is designed to have a higher equilibrium dissociation constant for binding to the antibody than the antibody's binding to the target, ensuring that it does not interfere when the antibody is cleaved. The CM is a polypeptide that can be cleaved by proteases co-localized with the target, allowing for targeted delivery of the conjugated agent. The patent also describes various types of antigen-binding fragments and linkers that can be employed in the method, emphasizing the versatility and specificity of the approach for therapeutic and diagnostic applications.
To know more about GlobalData’s detailed insights on CytomX Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
